38,678 Shares in Sierra Oncology (SRRA) Purchased by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Sierra Oncology (NASDAQ:SRRA) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 38,678 shares of the biotechnology company’s stock, valued at approximately $144,000. Cambridge Investment Research Advisors Inc. owned 0.07% of Sierra Oncology as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Candriam Luxembourg S.C.A. bought a new position in shares of Sierra Oncology in the fourth quarter valued at about $2,238,000. Jefferies Group LLC bought a new position in shares of Sierra Oncology in the fourth quarter valued at about $224,000. Iguana Healthcare Management LLC raised its holdings in shares of Sierra Oncology by 33.3% in the fourth quarter. Iguana Healthcare Management LLC now owns 800,000 shares of the biotechnology company’s stock valued at $2,984,000 after buying an additional 200,000 shares during the last quarter. Sphera Funds Management LTD. bought a new position in shares of Sierra Oncology in the fourth quarter valued at about $2,052,000. Finally, 683 Capital Management LLC bought a new position in shares of Sierra Oncology in the fourth quarter valued at about $3,438,000. 43.33% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Sierra Oncology stock opened at $1.87 on Friday. Sierra Oncology has a 12-month low of $1.10 and a 12-month high of $4.09. The stock has a market capitalization of $142.08, a P/E ratio of -2.23 and a beta of 2.38.

Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. During the same period in the prior year, the firm earned ($0.30) earnings per share. research analysts predict that Sierra Oncology will post -0.86 EPS for the current fiscal year.

SRRA has been the subject of a number of research analyst reports. Zacks Investment Research cut Sierra Oncology from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. ValuEngine raised Sierra Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 2nd.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://weekherald.com/2018/04/20/38678-shares-in-sierra-oncology-srra-purchased-by-cambridge-investment-research-advisors-inc.html.

Sierra Oncology Profile

Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.

Want to see what other hedge funds are holding SRRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sierra Oncology (NASDAQ:SRRA).

Institutional Ownership by Quarter for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply